neffyTM 2 mg
(epinephrine nasal spray)

No Needle. Small Device. Big Impact.

neffy™ is a needle-free, low-dose intranasal epinephrine nasal spray in clinical development for use as a rescue medication for people with Type 1 severe allergic reactions including anaphylaxis. neffy was designed to provide injection-like absorption of epinephrine, in a small, easy-to-carry, easy-to-use, rapidly administered, and reliable nasal spray device.

All systemic allergic reactions have the potential of progressing to anaphylaxis and becoming life-threatening. These reactions can be unpredictable and progress quickly to develop severe symptoms within a few minutes after exposure and can progress to a life-threatening event if not treated immediately.

Epinephrine is the first-line treatment for anaphylaxis.  Delay or failure to use epinephrine greatly increases the chance of hospitalization and has been associated with fatalities.  Epinephrine needs to be given as soon as symptoms occur because it is the only medication proven to stop a potentially life-threatening allergic reaction.

Needle-free and easy-to-use neffy may allow for improved patient and caregiver preparedness to give epinephrine quickly, confidently, and without hesitation that is caused by fear of the needle. Intended for use at the first signs of an allergic response, neffy is designed to provide patients and their families with a new option to rapidly resolve symptoms and prevent progression to severe anaphylaxis. 

Neffy2mgbackgrouind

2 mg is intended for individuals that are 30+ kg
1 mg is under development for children 15 to <30 kg

neffyTM 2 mg
(epinephrine nasal spray)

No Needle. Small Device. Big Impact.

neffy™ is a needle-free, low-dose intranasal epinephrine nasal spray in clinical development for use as a rescue medication for people with Type 1 severe allergic reactions including anaphylaxis. neffy was designed to provide injection-like absorption of epinephrine, in a small, easy-to-carry, easy-to-use, rapidly administered, and reliable nasal spray device.

All systemic allergic reactions have the potential of progressing to anaphylaxis and becoming life-threatening. These reactions can be unpredictable and progress quickly to develop severe symptoms within a few minutes after exposure and can progress to a life-threatening event if not treated immediately.

Epinephrine is the first-line treatment for anaphylaxis.  Delay or failure to use epinephrine greatly increases the chance of hospitalization and has been associated with fatalities.  Epinephrine needs to be given as soon as symptoms occur because it is the only medication proven to stop a potentially life-threatening allergic reaction.

Needle-free and easy-to-use neffy may allow for improved patient and caregiver preparedness to give epinephrine quickly, confidently, and without hesitation that is caused by fear of the needle. Intended for use at the first signs of an allergic response, neffy is designed to provide patients and their families with a new option to rapidly resolve symptoms and prevent progression to severe anaphylaxis. 

Neffy2mgbackgrouind

2 mg is intended for individuals that are 30+ kg
1 mg is under development for children 15 to <30 kg

We estimate approximately 25 million people in the United States have experienced severe Type 1 allergic reactions that may lead to anaphylaxis, but only about 3.3 million of them filled a prescription in 2021 for an epinephrine intra-muscular injectable device, including auto-injectors.*

Of those 3.3 million people, roughly half don’t carry these devices due to many drawbacks that can result in patient and caregiver injury, hesitation and delays in administration principally because of apprehension and pain of needles. In turn, the failure or delay of epinephrine delivery can allow the allergic reaction to progress in severity causing life-threatening symptoms or events that potentially require emergency services and/or hospitalization.1

Potential Benefits

No Needle. No Pain. No Fear.™

None of the serious risks associated with needle injectors. No fear of accidental lacerations or improper injections.

Easy-to-Use

Simple administration - just Place and Press. Less chance of failed dosing.

Pocket-Sized Protection

Readily available in a pocket or bag. Carry more than one device.

Proprietary Absorption Technology

Effective epinephrine absorption even with nasal congestion.

A Life-Threatening Problem

Epinephrine is the first-line therapy for severe allergic reactions, yet more than half of adult patients prescribed autoinjectors don’t use them when needed due to a range of reasons including:
  • fear of needles
  • bulkiness of the device
  • lack of proper training
  • misconception that epinephrine is only used once symptoms are most severe
These barriers prevent many patients and caregivers from carrying their devices regularly, leading to lack of readiness, added anxiety, and preventable tragedy.
ThreatAssessmentBoxV2

A Potentially Life-Changing Advancement

neffy™ (epinephrine nasal spray) is an innovative product in development for the treatment of severe allergic reactions that patients and caregivers may actually use because of its potentially breakthrough features, designed to provide:

Needle-free administration

Ease-of-Use

No risk of needle-related injuries or accidental injection in extremeties

Safe and consistent dosing of epinephrine

Proven device used reliably by other life-saving therapies

Small and light to ensure device can be ready-to-use anytime, anywhere

*Data on file

  1. Warren et al. Epinephrine auto-injector carriage and use practices among US children, adolescents and adults. Ann Allergy Asthma Immunol. 2018; 121(4): 479 – 489e2
  2. Data on file from ARS market research studies.
  3. Brooks et al. Diagnosis and treatment of food allergic reactions in pediatric emergency settings. Ann Allergy Asthma Immunol. 2017; 119(5): 467-468
  4. El Turki et al. A systematic review of patients’, parents’ and healthcare professionals’ adrenaline auto-injector administration techniques. Emergency Medical Journal. 2017; 34(6): 403-416
  5. Asthma and Allergy Foundation of America. My Life with Food Allergy Patient Survey Report 2019